• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

FDA Drug Safety Communication: Planned return of CardioGen-82 to market with new Boxed Warning

(en Español)

This update is in follow-up to the Drug Safety Communication: Update: Preliminary findings from ongoing investigations of CardioGen-82 issued on 1/12/2012.

 

Safety Announcement

[2-15-2012] The U.S. Food and Drug Administration (FDA) is notifying healthcare professionals; in particular, the medical imaging community; about the planned return of CardioGen-82 to the U.S. market following the voluntary recall by the manufacturer, Bracco Diagnostics, Inc., on July 25, 2011. FDA has approved revised labeling for CardioGen-82 to include a Boxed Warning and enhanced testing information to help minimize the risk for exposure to unintended levels of strontium radiation. 

CardioGen-82 consists of a generator that is used at clinical sites to produce rubidium (Rb)-82 chloride injection. Tests for strontium and rubidium radioactivity are performed upon the fluid (eluate) obtained from the generator. The revised labeling establishes new "Alert Limits" for strontium-82 (Sr-82) and strontium-85 (Sr-85) levels in the generator eluate. If the eluate reaches these Alert Limits, then additional Sr-82 and Sr-85 eluate testing is required. Previously, eluate testing was done only once a day; with the revised labeling, the testing is still done daily, but additional tests are performed that day if a generator eluate has reached the Alert Limit. The additional daily testing is necessary to promptly identify excess strontium levels which indicate that the generator expiration is approaching. The revised labeling also includes new information to identify when a generator is expired and its use must stop. 

To minimize the risk of increased radiation exposure in patients, clinical sites should strictly follow the new directions for use of the CardioGen-82 generator in the labeling. Clinical sites and healthcare professionals can access the latest CardioGen-82 labeling here

Clinical sites are also reminded to review and update the instructions for their dose calibrators to ensure proper isotope readings are performed in the eluate testing procedures.

 

Contact FDA

1-800-332-1088
1-800-FDA-0178 Fax
Report a Serious Problem

MedWatch Online

Regular Mail: Use postage-paid FDA Form 3500

Mail to: MedWatch 5600 Fishers Lane

Rockville, MD 20857